非酒精性脂肪性肝炎（NASH）：针对NASH中凋亡信号调节激酶1（ASK1）的新型治疗策略。 - Suppr | 超能文献

相似文献

1

NASH: Novel therapeutic strategies targeting ASK1 in NASH.非酒精性脂肪性肝炎（NASH）：针对NASH中凋亡信号调节激酶1（ASK1）的新型治疗策略。

Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):329-330. doi: 10.1038/nrgastro.2017.42. Epub 2017 Apr 5.

2

The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis.去泛素化酶 TNFAIP3 介导的肝 ASK1 失活可改善非酒精性脂肪性肝炎。

Nat Med. 2018 Jan;24(1):84-94. doi: 10.1038/nm.4453. Epub 2017 Dec 11.

3

Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.靶向胱天蛋白酶 8 和 FADD 样凋亡调节蛋白可改善小鼠和非人灵长类动物的非酒精性脂肪性肝炎。

Nat Med. 2017 Apr;23(4):439-449. doi: 10.1038/nm.4290. Epub 2017 Feb 20.

4

Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates.抗腺相关病毒（AAV）中和抗体的影响是将基因转移至非人灵长类动物时的一个关键考量因素。

Nat Med. 2018 Jun;24(6):699. doi: 10.1038/s41591-018-0062-2.

5

Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis.用于评估非酒精性脂肪性肝炎疾病严重程度的凋亡和抗凋亡血清标志物。

Arab J Gastroenterol. 2014 Mar;15(1):6-11. doi: 10.1016/j.ajg.2014.01.009. Epub 2014 Feb 7.

6

CD44 is a key player in non-alcoholic steatohepatitis.CD44 是非酒精性脂肪性肝炎的关键参与者。

J Hepatol. 2017 Aug;67(2):328-338. doi: 10.1016/j.jhep.2017.03.003. Epub 2017 Mar 16.

7

An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease.一项探索性研究，考察纳米液相色谱-质谱联用和磷酸化蛋白质组学如何区分非酒精性脂肪性肝病中晚期纤维化和更高百分比胶原的患者。

BMC Med. 2018 Sep 12;16(1):170. doi: 10.1186/s12916-018-1136-1.

8

Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病

Adv Exp Med Biol. 2017;960:443-467. doi: 10.1007/978-3-319-48382-5_19.

9

The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.蓝莓汁与益生菌的组合通过PPAR-α影响SREBP-1c/PNPLA-3途径改善非酒精性脂肪性肝炎（NASH）。

Nutrients. 2017 Feb 27;9(3):198. doi: 10.3390/nu9030198.

10

Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎患儿循环可溶性Fas和Fas配体水平升高。

Dig Dis Sci. 2015 Aug;60(8):2353-9. doi: 10.1007/s10620-015-3614-z. Epub 2015 Mar 13.

引用本文的文献

1

Rational design and discovery of potent PROTAC degraders of ASK1: a targeted therapy in MASH.ASK1强效PROTAC降解剂的合理设计与发现：非酒精性脂肪性肝炎的靶向治疗

RSC Med Chem. 2025 Jun 6. doi: 10.1039/d5md00252d.

2

The role of ubiquitination and deubiquitination in the pathogenesis of non-alcoholic fatty liver disease.泛素化与去泛素化在非酒精性脂肪性肝病发病机制中的作用

Front Immunol. 2025 Apr 11;16:1535362. doi: 10.3389/fimmu.2025.1535362. eCollection 2025.

3

The emerging role of E3 ubiquitin ligases and deubiquitinases in metabolic dysfunction-associated steatotic liver disease.

本文引用的文献

1

Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates.靶向胱天蛋白酶 8 和 FADD 样凋亡调节蛋白可改善小鼠和非人灵长类动物的非酒精性脂肪性肝炎。

Nat Med. 2017 Apr;23(4):439-449. doi: 10.1038/nm.4290. Epub 2017 Feb 20.

2

Pleiotropic properties of ASK1.ASK1 的多效性。

Biochim Biophys Acta Gen Subj. 2017 Jan;1861(1 Pt A):3030-3038. doi: 10.1016/j.bbagen.2016.09.028. Epub 2016 Sep 30.

3

DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity.